These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9432695)

  • 1. [Women's hearts are hard to break. Coronary heart diseases--is the woman a special case!?].
    Newnham HH; Silberberg J
    Praxis (Bern 1994); 1997 Oct; 86(43):1698-700. PubMed ID: 9432695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease.
    Mohandas B; Mehta JL
    Curr Opin Cardiol; 2007 Sep; 22(5):434-42. PubMed ID: 17762545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease.
    Windler E; Zyriax BC; Eidenmüller B; Boeing H
    Maturitas; 2007 Jul; 57(3):239-46. PubMed ID: 17292571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.
    Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
    Bone; 2008 Feb; 42(2):294-306. PubMed ID: 18053789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary heart disease risk factors in women: focus on gender differences.
    Rao AV
    J La State Med Soc; 1998 Feb; 150(2):67-72. PubMed ID: 9510611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmenopausal hormones and coronary artery disease: potential benefits and risks.
    Lobo RA
    Climacteric; 2007 Oct; 10 Suppl 2():21-6. PubMed ID: 17882668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single mathematical model predicts physicians' recommendations and postmenopausal women's decisions to participate in a clinical trial to prevent breast cancer or coronary heart disease.
    Veit CT
    Med Decis Making; 2004; 24(4):330-50. PubMed ID: 15271272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raising awareness of women and heart disease--women's hearts are different.
    Herrmann C
    Crit Care Nurs Clin North Am; 2008 Sep; 20(3):251-63. PubMed ID: 18644507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the value of mass screening for coronary risks.
    Leaman DM; Crawshaw SL; Zelis RF
    Pa Med; 1981 Feb; 84(2):29-31. PubMed ID: 6785708
    [No Abstract]   [Full Text] [Related]  

  • 10. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of coronary heart disease by early postmenopausal hormone therapy: new supporting data].
    Gaspard U
    J Gynecol Obstet Biol Reprod (Paris); 2008 Jun; 37(4):340-5. PubMed ID: 18249506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence?
    Salpeter S
    Climacteric; 2005 Dec; 8(4):307-10. PubMed ID: 16390764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
    Hayashino Y; Shimbo T; Tsujii S; Ishii H; Kondo H; Nakamura T; Nagata-Kobayashi S; Fukui T
    Int J Cardiol; 2007 May; 118(1):88-96. PubMed ID: 16949690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of hormone replacement therapy in Washington State: is prevention being put into practice?
    Saver BG; Taylor TR; Woods NF
    J Fam Pract; 1999 May; 48(5):364-71. PubMed ID: 10334613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.
    Grodstein F; Manson JE; Stampfer MJ
    J Womens Health (Larchmt); 2006; 15(1):35-44. PubMed ID: 16417416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E; Canfell K
    Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy and cardiovascular disease revisited.
    Stevenson JC
    Menopause Int; 2009 Jun; 15(2):55-7. PubMed ID: 19465669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronary heart disease risk factors in women.
    Brochier ML; Arwidson P
    Eur Heart J; 1998 Feb; 19 Suppl A():A45-52. PubMed ID: 9519343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.